Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN

INCLUSION CRITERIA

   - Pathologically-proven ovarian cancer, or cancer of mullerian origin, that was or will
   be treated with a 1st-line taxane plus a platinum-based chemotherapy regimen.

   - GROUP A (painful neuropathy group): Subjective symptoms of painful peripheral
   neuropathy (burning, stabbing, throbbing, painful tingling, aching in the fingers
   and/or toes) that is greater than or equal to 10 on a scale of 0 to 100 in the
   neuropathic pain questionnaire

   - GROUP B (painless neuropathy group): Subjective symptoms of painless neuropathy (loss
   of sensation, worsening balance, strange sensation in fingers and/or toes) or no
   complaints related to neuropathy.

   - Life expectancy of 6 months

   - Ability to understand the study protocol, participate in testing, and the willingness
   to sign a written informed consent document.

EXCLUSION CRITERIA

   - Received prior chemotherapy for ovarian cancer or cancer of mullerian origin other
   than 1st-line treatment with a taxane + platinum based regimen.

   - No concurrent investigational drugs.

   - Received investigational drugs suspected to cause peripheral neuropathy.

   - History of B12 deficiency

   - History of neuropathy or numbness/tingling suspicious for neuropathy, prior to the
   first dose of chemotherapy for ovarian cancer

   - Prior treatment for other cancers that included drugs known to cause neuropathy
   (including but are not limited to vinca-alkaloids, platinums, taxanes, bortizomib).

   - Known peripheral vascular disease

   - Chronic daily headache or headache for more than 14 days of the month

   - Pain rated 50 or higher on a scale of 0 to 100, with 0 = no pain at all and 100 =
   worst pain imaginable.

   - Pregnant or nursing

   - HIV-positive

   - Do not speak or read English